364 related articles for article (PubMed ID: 9554627)
1. Cytomegalovirus viremia in lung transplant recipients receiving ganciclovir and immune globulin.
Gutiérrez CA; Chaparro C; Krajden M; Winton T; Kesten S
Chest; 1998 Apr; 113(4):924-32. PubMed ID: 9554627
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus immunoglobulin decreases the risk of cytomegalovirus infection but not disease after pediatric lung transplantation.
Ranganathan K; Worley S; Michaels MG; Arrigan S; Aurora P; Ballmann M; Boyer D; Conrad C; Eichler I; Elidemir O; Goldfarb S; Mallory GB; Mogayzel PJ; Parakininkas D; Solomon M; Visner G; Sweet SC; Faro A; Danziger-Isakov L
J Heart Lung Transplant; 2009 Oct; 28(10):1050-6. PubMed ID: 19782286
[TBL] [Abstract][Full Text] [Related]
3. Impact of prophylaxis with cytogam alone on the incidence of CMV viremia in CMV-seropositive lung transplant recipients.
Kruger RM; Paranjothi S; Storch GA; Lynch JP; Trulock EP
J Heart Lung Transplant; 2003 Jul; 22(7):754-63. PubMed ID: 12873543
[TBL] [Abstract][Full Text] [Related]
4. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation.
Ruttmann E; Geltner C; Bucher B; Ulmer H; Höfer D; Hangler HB; Semsroth S; Margreiter R; Laufer G; Müller LC
Transplantation; 2006 May; 81(10):1415-20. PubMed ID: 16732179
[TBL] [Abstract][Full Text] [Related]
5. Failure of prophylactic ganciclovir to prevent cytomegalovirus disease in recipients of lung transplants.
Bailey TC; Trulock EP; Ettinger NA; Storch GA; Cooper JD; Powderly WG
J Infect Dis; 1992 Mar; 165(3):548-52. PubMed ID: 1311352
[TBL] [Abstract][Full Text] [Related]
6. Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients.
Bonaros NE; Kocher A; Dunkler D; Grimm M; Zuckermann A; Ankersmit J; Ehrlich M; Wolner E; Laufer G
Transplantation; 2004 Mar; 77(6):890-7. PubMed ID: 15077033
[TBL] [Abstract][Full Text] [Related]
7. Risk Factors Associated with Survival Following Ganciclovir Prophylaxis through Day +100 in Cytomegalovirus At-Risk Pediatric Allogeneic Stem Cell Transplantation Recipients: Development of Cytomegalovirus Viremia Associated with Significantly Decreased 1-Year Survival.
Klejmont LM; Mo X; Milner J; Harrison L; Morris E; van de Ven C; Cairo MS
Transplant Cell Ther; 2024 Jan; 30(1):103.e1-103.e8. PubMed ID: 37806447
[TBL] [Abstract][Full Text] [Related]
8. Use of cytomegalovirus immune globulin and ganciclovir for the prevention of cytomegalovirus disease in lung transplantation.
Zamora MR
Transpl Infect Dis; 2001; 3 Suppl 2():49-56. PubMed ID: 11926751
[TBL] [Abstract][Full Text] [Related]
9. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation.
Gerbase MW; Dubois D; Rothmeier C; Spiliopoulos A; Wunderli W; Nicod LP
Chest; 1999 Nov; 116(5):1265-72. PubMed ID: 10559085
[TBL] [Abstract][Full Text] [Related]
10. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of prolonged cytomegalovirus prophylaxis with intravenous ganciclovir in pediatric and young adult lung transplant recipients.
Spivey JF; Singleton D; Sweet S; Storch GA; Hayashi RJ; Huddleston CB; Danziger-Isakov LA
Pediatr Transplant; 2007 May; 11(3):312-8. PubMed ID: 17430489
[TBL] [Abstract][Full Text] [Related]
12. Management of allogeneic bone marrow transplant recipients at risk for cytomegalovirus disease using a surveillance bronchoscopy and prolonged pre-emptive ganciclovir therapy.
Reddy V; Hao Y; Lipton J; Meharchand J; Minden M; Mazzulli T; Chan C; Messner HA
J Clin Virol; 1999 Aug; 13(3):149-59. PubMed ID: 10443791
[TBL] [Abstract][Full Text] [Related]
13. Intravenous ganciclovir prophylaxis for cytomegalovirus in heart, heart-lung, and lung transplant recipients.
Wreghitt TG; Abel SJ; McNeil K; Parameshwar J; Stewart S; Cary N; Sharples L; Large S; Wallwork J
Transpl Int; 1999; 12(4):254-60. PubMed ID: 10460870
[TBL] [Abstract][Full Text] [Related]
14. Lack of association between beta-herpesvirus infection and bronchiolitis obliterans syndrome in lung transplant recipients in the era of antiviral prophylaxis.
Manuel O; Kumar D; Moussa G; Chen MH; Pilewski J; McCurry KR; Studer SM; Crespo M; Husain S; Humar A
Transplantation; 2009 Mar; 87(5):719-25. PubMed ID: 19295317
[TBL] [Abstract][Full Text] [Related]
15. Prevention of recurrent cytomegalovirus disease in renal and liver transplant recipients: effect of oral ganciclovir.
Turgeon N; Fishman JA; Doran M; Basgoz N; Tolkoff-Rubin NE; Cosimi AB; Rubin RH
Transpl Infect Dis; 2000 Mar; 2(1):2-10. PubMed ID: 11429003
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis.
Wiita AP; Roubinian N; Khan Y; Chin-Hong PV; Singer JP; Golden JA; Miller S
Transpl Infect Dis; 2012 Jun; 14(3):248-58. PubMed ID: 22385394
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis.
Mitsani D; Nguyen MH; Kwak EJ; Silveira FP; Vadnerkar A; Pilewski J; Crespo M; Toyoda Y; Bermudez C; Clancy CJ
J Heart Lung Transplant; 2010 Sep; 29(9):1014-20. PubMed ID: 20598582
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus Immunoglobulin for Prophylaxis and Treatment of Cytomegalovirus Infection in the (Val)Ganciclovir Era: A Single-Center Experience.
Lopez Garcia-Gallo C; García Fadul C; Laporta R; Portero F; Millan I; Ussetti P
Ann Transplant; 2015 Nov; 20():661-6. PubMed ID: 26537426
[TBL] [Abstract][Full Text] [Related]
19. Combination prophylaxis with ganciclovir and cytomegalovirus (CMV) immune globulin after lung transplantation: effective CMV prevention following daclizumab induction.
Weill D; Lock BJ; Wewers DL; Young KR; Zorn GL; Early L; Kirklin JK; McGiffin DC
Am J Transplant; 2003 Apr; 3(4):492-6. PubMed ID: 12694074
[TBL] [Abstract][Full Text] [Related]
20. Ganciclovir for cytomegalovirus: a call for indefinite prophylaxis in lung transplantation.
Valentine VG; Weill D; Gupta MR; Raper B; Laplace SG; Lombard GA; Bonvillain RW; Taylor DE; Dhillon GS
J Heart Lung Transplant; 2008 Aug; 27(8):875-81. PubMed ID: 18656801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
